An international team of researchers has shown that the myofibroblast-expressed integrin alpha(V) subunit drives fibrosis and that a small molecule integrin alpha(V) antagonist from Antegrin Therapeutics can attenuate the process in mice. The biotech is developing an improved version of the compound for pulmonary fibrosis.